Managing Progressive Non-Small Cell Lung Cancer
Meeting Series
Meeting Series

Managing Progressive Non-Small Cell Lung Cancer

Second-Line Therapy and Beyond

Not a member of My prIME? Join now for instant access.

These CME-certified meetings will discuss the rapidly changing treatment landscape in advanced lung cancer with a focus on second- and later-line treatment options for patients with non-oncogene driven adenocarcinoma and squamous non-small cell lung cancer (NSCLC), including immunotherapy and chemotherapy in combination with antiangiogenic agents. Factors that may impact treatment selection will be evaluated in the context of a clinical case.



1.0 AMA PRA Category 1 Credit™

  • Welcome and introduction
  • Treatment algorithm for advanced NSCLC: Focus on choices after progression on first-line therapy in non-driver NSCLC
  • Factors influencing second- and later-line treatment decisions
  • Interactive case-based discussion
  • prIME Points™
  • Adjourn

  • Leora Horn, MD, MScVanderbilt-Ingram Cancer Center
    Nashville, Tennessee, United States
  • Benjamin P. Levy, MDJohns Hopkins Sidney Kimmel Cancer Center
    Washington, DC, United States
  • Aaron Lisberg, MDUCLA Medicine
    Los Angeles, California, United States
  • Rathi Pillai, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

This educational meeting series is designed for the healthcare team that treats and manages patients with lung cancer including: Medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, surgeons, nurses, nurse practitioners, physician assistants, and other healthcare professionals.

After successful completion of this educational activity, participants should be able to:

  • Identify patient and disease characteristics to be considered during treatment decision making for patients with progressive NSCLC
  • Assess second- and third-line treatment options for advanced squamous and nonsquamous NSCLC, including immunotherapy and antiangiogenic therapy
  • Select the optimal sequence of therapy for individual patients with advanced NSCLC who progressed on platinum-based therapy and/or immunotherapy

This educational activity is supported by a grant from Lilly.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Daphaney Willis prior to the live event at 678.686.7759.

There is no fee for this activity.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.